When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study
- PMID: 21502648
- PMCID: PMC3610527
- DOI: 10.7326/0003-4819-154-8-201104190-00001
When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study
Abstract
Background: Most clinical guidelines recommend that AIDS-free, HIV-infected persons with CD4 cell counts below 0.350 × 10(9) cells/L initiate combined antiretroviral therapy (cART), but the optimal CD4 cell count at which cART should be initiated remains a matter of debate.
Objective: To identify the optimal CD4 cell count at which cART should be initiated.
Design: Prospective observational data from the HIV-CAUSAL Collaboration and dynamic marginal structural models were used to compare cART initiation strategies for CD4 thresholds between 0.200 and 0.500 × 10(9) cells/L.
Setting: HIV clinics in Europe and the Veterans Health Administration system in the United States.
Patients: 20, 971 HIV-infected, therapy-naive persons with baseline CD4 cell counts at or above 0.500 × 10(9) cells/L and no previous AIDS-defining illnesses, of whom 8392 had a CD4 cell count that decreased into the range of 0.200 to 0.499 × 10(9) cells/L and were included in the analysis.
Measurements: Hazard ratios and survival proportions for all-cause mortality and a combined end point of AIDS-defining illness or death.
Results: Compared with initiating cART at the CD4 cell count threshold of 0.500 × 10(9) cells/L, the mortality hazard ratio was 1.01 (95% CI, 0.84 to 1.22) for the 0.350 threshold and 1.20 (CI, 0.97 to 1.48) for the 0.200 threshold. The corresponding hazard ratios were 1.38 (CI, 1.23 to 1.56) and 1.90 (CI, 1.67 to 2.15), respectively, for the combined end point of AIDS-defining illness or death.
Limitations: CD4 cell count at cART initiation was not randomized. Residual confounding may exist.
Conclusion: Initiation of cART at a threshold CD4 count of 0.500 × 10(9) cells/L increases AIDS-free survival. However, mortality did not vary substantially with the use of CD4 thresholds between 0.300 and 0.500 × 10(9) cells/L.
Conflict of interest statement
Figures
Comment in
-
If we can't get what we want, can we get what we need? optimizing use of antiretroviral therapy in the current era.Ann Intern Med. 2011 Apr 19;154(8):563-5. doi: 10.7326/0003-4819-154-8-201104190-00009. Ann Intern Med. 2011. PMID: 21502654 Free PMC article. No abstract available.
Similar articles
-
Long-term trends in mortality and AIDS-defining events after combination ART initiation among children and adolescents with perinatal HIV infection in 17 middle- and high-income countries in Europe and Thailand: A cohort study.PLoS Med. 2018 Jan 30;15(1):e1002491. doi: 10.1371/journal.pmed.1002491. eCollection 2018 Jan. PLoS Med. 2018. PMID: 29381702 Free PMC article.
-
Pretreatment CD4 cell slope and progression to AIDS or death in HIV-infected patients initiating antiretroviral therapy--the CASCADE collaboration: a collaboration of 23 cohort studies.PLoS Med. 2010 Feb 23;7(2):e1000239. doi: 10.1371/journal.pmed.1000239. PLoS Med. 2010. PMID: 20186270 Free PMC article.
-
Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda.Ann Intern Med. 2011 Aug 16;155(4):209-16. doi: 10.7326/0003-4819-155-4-201108160-00358. Epub 2011 Jul 18. Ann Intern Med. 2011. PMID: 21768555
-
Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies.Lancet. 2009 Apr 18;373(9672):1352-63. doi: 10.1016/S0140-6736(09)60612-7. Epub 2009 Apr 8. Lancet. 2009. PMID: 19361855 Free PMC article. Review.
-
Antiretroviral treatment regardless of CD4 count: the universal answer to a contextual question.AIDS Res Ther. 2016 Jul 26;13:27. doi: 10.1186/s12981-016-0111-1. eCollection 2016. AIDS Res Ther. 2016. PMID: 27462361 Free PMC article. Review.
Cited by
-
Optimal P2Y12 inhibitor durations in older men and older women following an acute myocardial infarction: A nationwide cohort study using Medicare data.Am Heart J Plus. 2023 Dec;36:100339. doi: 10.1016/j.ahjo.2023.100339. Epub 2023 Oct 31. Am Heart J Plus. 2023. PMID: 38487715 Free PMC article.
-
Early Mortality After the First Dose of COVID-19 Vaccination: A Target Trial Emulation.Clin Infect Dis. 2024 Mar 20;78(3):625-632. doi: 10.1093/cid/ciad604. Clin Infect Dis. 2024. PMID: 38319989 Free PMC article.
-
Ranking tailoring variables for constructing individualized treatment rules: an application to schizophrenia.J R Stat Soc Ser C Appl Stat. 2022 Mar;71(2):309-330. doi: 10.1111/rssc.12533. Epub 2022 Mar 20. J R Stat Soc Ser C Appl Stat. 2022. PMID: 38288004 Free PMC article.
-
Real-World Continuous EEG Utilization and Outcomes in Hospitalized Patients With Acute Cerebrovascular Diseases.J Clin Neurophysiol. 2023 Oct 30:10.1097/WNP.0000000000001043. doi: 10.1097/WNP.0000000000001043. Online ahead of print. J Clin Neurophysiol. 2023. PMID: 37938032
-
Lung cancer screening adherence among people living with and without HIV: An analysis of an integrated health system in Florida, United States (2012-2021).Prev Med Rep. 2023 Jul 21;35:102334. doi: 10.1016/j.pmedr.2023.102334. eCollection 2023 Oct. Prev Med Rep. 2023. PMID: 37546581 Free PMC article.
References
-
- Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997;337:725–33. - PubMed
-
- Cameron DW, Heath-Chiozzi M, Danner S, Cohen C, Kravcik S, Maurath C, et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet. 1998;351:543–9. - PubMed
-
- Sterne JA, Hernán MA, Ledergerber B, Tilling K, Weber R, Sendi P, et al. Swiss HIV Cohort Study. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet. 2005;336:378–84. - PubMed
-
- Cole SR, Hernán MA, Robins JM, Anastos K, Chmiel J, Detels R, et al. Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. Am J Epidemiol. 2003;158:687–94. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials